xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06031064</url>
    </required_header>
    <id_info>
      <org_study_id>P/22-108</org_study_id>
      <nct_id>NCT06031064</nct_id>
    </id_info>
    <brief_title>External Validation of a Microscopic Colitis Clinical Scoring System in Patients With Chronic Watery Diarrhoea</brief_title>
    <official_title>External Validation of a Clinical Scoring System to Predict Microscopic Colitis in Patients With Chronic Watery Diarrhoea</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Hospital Mutua de Terrassa</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Hospital Mutua de Terrassa</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Chronic watery diarrhoea is a very common problem in the population and most of these&#xD;
        patients will be referred for colonoscopy. If no macroscopic findings are observed during&#xD;
        colonoscopy to justify the diarrhoea, serial colonic biopsies will be taken to rule out&#xD;
        Microscopic Colitis (MC). However, it has been estimated that only 10-15% of these patients&#xD;
        will be diagnosed with MC after colonoscopy. Therefore, about 80% of the biopsies collected&#xD;
        and analysed will not be useful to establish a diagnosis, considerably increasing costs.&#xD;
  &#xD;
        To predict the risk of developing MC, a new promising clinical scoring system has been&#xD;
        recently developed. This score will be useful in the diagnostic work-up of chronic watery&#xD;
        diarrhoea to prioritize colonoscopy with stepwise colonic biopsies in patients with a&#xD;
        positive highly specific score for MC. In cases with a negative score, colonoscopy plus&#xD;
        biopsies should be performed only if other diagnostic tests are negative.&#xD;
  &#xD;
        The aim of this current study is to externally validate the new scoring system to predict MC&#xD;
        in patients with chronic watery diarrhoea.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Two diagnostic scoring systems have been proposed to predict the risk of developing MC: 1)&#xD;
        The Kane score (sensitivity (SN) 96%; specificity (SP) 46%) combines eight risk factors,&#xD;
        including female sex, age over 50 years, weight loss, absence of abdominal pain, and use of&#xD;
        proton pump inhibitors (PPIs) and non-steroidal anti-inflammatory drugs (NSAIDs), presence of&#xD;
        nocturnal diarrhoea and diarrhoea duration of less than 6 months. 2) The Cotter score (SN&#xD;
        93%; SP 49%) includes age ≥55 years, duration of diarrhoea ≤6 months, ≥5 bowel movements per&#xD;
        day, body mass index &lt;30 kg/m2, current smoking, and current use of selective serotonin&#xD;
        reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors and NSAIDs. However, both&#xD;
        scoring systems have been derived from retrospective studies and watery chronic diarrhoea,&#xD;
        the hallmark clinical symptom of MC, was not well defined.&#xD;
  &#xD;
        Besides MC risk factors, faecal markers could also be useful for MC screening. Most studies&#xD;
        have found that 60-75% of the patients with active collagenous colitis, a subtype of MC, have&#xD;
        elevated faecal calprotectin levels. Moreover, a recent study showed that faecal calprotectin&#xD;
        concentrations &gt;100 μg/g (AUC, 0.73) showed a 67% sensitivity and 75% specificity to predict&#xD;
        MC.&#xD;
  &#xD;
        To further assess the value of the Kane and Cotter scoring systems and to derive a new score&#xD;
        including faecal calprotectin aiming to increase specificity, the investigators performed a&#xD;
        prospective observational two-centres study. Chronic watery diarrhoea was defined as ≥2&#xD;
        watery stools (Bristol 6-7) per day, of frequent occurrence (≥3 times per week), of at least&#xD;
        1 month duration. A registry of demographic and clinical characteristics (VAS of 0-100 of&#xD;
        abdominal pain and abdominal distension, presence of nocturnal diarrhoea, urgency and faecal&#xD;
        incontinence, smoking, body mass index, weight loss, use of drugs) was performed. The study&#xD;
        included 118 patients with chronic watery diarrhoea, from which 41 were diagnosed with MC (21&#xD;
        lymphocytic colitis, 16 collagenous colitis and 4 paucicellular colitis) and obtained lower&#xD;
        SN and SP values than those published of the Cotter (SN 78%; SP 57%) and Kane (SN 78%; SP&#xD;
        38%) scores. The AUC of both scores was 0.71 and 0.66, respectively. The multivariate&#xD;
        analysis identified 5 variables associated with MC: &gt;5 stools/day (OR 12.5), duration of&#xD;
        diarrhoea ≤8 months (OR 5), regular use of low-dose acetylsalicylic acid (ASA) (OR 4), BMI&#xD;
        ≤26 Kg/m2 (OR 4.1) and faecal calprotectin &gt;500 µg/g (OR 5.5). A new score was developed&#xD;
        using the variables mentioned above with an AUC of 0.86 (p&lt;0.001 vs. Kane and Cotter scores).&#xD;
        A score &gt;10 had a sensitivity of 61.5% and a specificity of 92%. A score &gt;17 gave a&#xD;
        specificity of 100% with a sensitivity of 36%. The score was internally validated using&#xD;
        bootstrapping techniques.&#xD;
  &#xD;
        Although promising, the new scoring system must be externally validated before generalizing&#xD;
        its use in clinical practice.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">May 15, 2022</start_date>
    <completion_date type="Anticipated">February 1, 2024</completion_date>
    <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Percentage of patients diagnosed with Microscopic Colitis (MC)</measure>
      <time_frame>up to 2 months (after clinical and histological assessment)</time_frame>
      <description>MC diagnosis based on clinical and histological criteria as established by the European guidelines on microscopic colitis: Miehlke S, Guagnozzi D, Zabana Y, et al. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations [published online ahead of print, 2021 Feb 22]. United European Gastroenterol J. 2021;9(1):13-37</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Faecal calprotectin concentration (μg/g)</measure>
      <time_frame>at inclusion (prior to colonoscopy)</time_frame>
      <description>Faecal calprotectin concentration (μg/g) will be measured using a DSX system analyser (Dynex technologies, Worthing, UK) by ELISA (BÜHLMANN fCAL, Schönenbuch, Switzerland or similar)</description>
    </secondary_outcome>
    <number_of_groups>1</number_of_groups>
    <enrollment type="Anticipated">200</enrollment>
    <condition>Microscopic Colitis</condition>
    <arm_group>
      <arm_group_label>Patients with chronic watery diarrhoea and clinical suspicion of MC</arm_group_label>
    </arm_group>
    <biospec_retention>Samples With DNA</biospec_retention>
    <biospec_descr>
      <textblock>
        Frozen colon tissue and faecal sample&#xD;
      </textblock>
    </biospec_descr>
    <eligibility>
      <study_pop>
        <textblock>
          Patients derived at the digestive system department with chronic watery diarrhoea and&#xD;
          clinical suspicion of MC, requiring colonoscopy with biopsies to complete the study&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age 40 years or older.&#xD;
  &#xD;
            -  Patient with chronic non-bloody watery diarrhoea (Bristol scale=6 or 7), with 2 or&#xD;
               more liquid stools per day, of frequent occurrence (at least 3 times per week), of at&#xD;
               least 1 month's duration.&#xD;
  &#xD;
            -  Normal blood test and biochemistry (including C reactive protein and TSH), negative&#xD;
               anti-transglutaminase antibodies, and negative faecal ova and parasites. A 75SeHCAT is&#xD;
               not mandatory.&#xD;
  &#xD;
            -  Patients with an indication for a diagnostic colonoscopy by their physician at charge,&#xD;
               mainly to rule out MC.&#xD;
  &#xD;
            -  Signature of the study informed consent&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Patients with either alternating diarrhoea-constipation or self-limiting diarrhoea at&#xD;
               the time of colonoscopy.&#xD;
  &#xD;
            -  History of inflammatory bowel disease or coeliac disease, bile acid diarrhoea.&#xD;
  &#xD;
            -  Previous gastrointestinal surgery (excluding appendectomy or inguinal herniorrhaphy).&#xD;
  &#xD;
            -  Incomplete colonoscopy or no colon biopsies of at least right and left colon in&#xD;
               separate containers (minimum 2 samples of each segment).&#xD;
  &#xD;
            -  Unsatisfactory preparation for a complete exploration (Boston scale &lt;6, any segment&#xD;
               &lt;2)&#xD;
  &#xD;
            -  Significant macroscopic lesions on colonoscopy, other than those occasionally&#xD;
               described in MC&#xD;
  &#xD;
            -  Inability to understand the instructions for participating in the study.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>40 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Yamile Zabana, MD, PhD</last_name>
      <email>yzabana@gmail.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>Hospital Universitari MútuaTerrassa</name>
        <address>
          <city>Terrassa</city>
          <state>Barcelona</state>
          <zip>08221</zip>
          <country>Spain</country>
        </address>
      </facility>
      <status>Recruiting</status>
    </location>
    <location_countries>
      <country>Spain</country>
    </location_countries>
    <reference>
      <citation>Miehlke S, Guagnozzi D, Zabana Y, Tontini GE, Kanstrup Fiehn AM, Wildt S, Bohr J, Bonderup O, Bouma G, D'Amato M, Heiberg Engel PJ, Fernandez-Banares F, Macaigne G, Hjortswang H, Hultgren-Hornquist E, Koulaouzidis A, Kupcinskas J, Landolfi S, Latella G, Lucendo A, Lyutakov I, Madisch A, Magro F, Marlicz W, Mihaly E, Munck LK, Ostvik AE, Patai AV, Penchev P, Skonieczna-Zydecka K, Verhaegh B, Munch A. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. United European Gastroenterol J. 2021 Feb 22;9(1):13-37. doi: 10.1177/2050640620951905. Online ahead of print.</citation>
      <PMID>33619914</PMID>
    </reference>
    <reference>
      <citation>Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005 Aug 15;22(4):277-84. doi: 10.1111/j.1365-2036.2005.02561.x.</citation>
      <PMID>16097993</PMID>
    </reference>
    <reference>
      <citation>Larsson JK, Sjoberg K, Vigren L, Benoni C, Toth E, Olesen M. Chronic non-bloody diarrhoea: a prospective study in Malmo, Sweden, with focus on microscopic colitis. BMC Res Notes. 2014 Apr 14;7:236. doi: 10.1186/1756-0500-7-236.</citation>
      <PMID>24731750</PMID>
    </reference>
    <reference>
      <citation>Fernandez-Banares F, de Sousa MR, Salas A, Beltran B, Piqueras M, Iglesias E, Gisbert JP, Lobo B, Puig-Divi V, Garcia-Planella E, Ordas I, Andreu M, Calvo M, Montoro M, Esteve M, Viver JM; RECOMINA Project, GETECCU Grupo Espanol de Enfermedades de Crohn y Colitis Ulcerosa. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013 Feb;19(2):411-7. doi: 10.1002/ibd.23009.</citation>
      <PMID>23344243</PMID>
    </reference>
    <reference>
      <citation>Kane JS, Rotimi O, Everett SM, Samji S, Michelotti F, Ford AC. Development and validation of a scoring system to identify patients with microscopic colitis. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1125-31. doi: 10.1016/j.cgh.2014.12.035. Epub 2015 Jan 20.</citation>
      <PMID>25616029</PMID>
    </reference>
    <reference>
      <citation>Kane JS, Sood R, Law GR, Gracie DJ, To N, Gold MJ, Ford AC. Validation and modification of a diagnostic scoring system to predict microscopic colitis. Scand J Gastroenterol. 2016 Oct;51(10):1206-12. doi: 10.1080/00365521.2016.1186221. Epub 2016 May 31.</citation>
      <PMID>27243102</PMID>
    </reference>
    <reference>
      <citation>Cotter TG, Binder M, Harper EP, Smyrk TC, Pardi DS. Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. J Clin Gastroenterol. 2017 Mar;51(3):228-234. doi: 10.1097/MCG.0000000000000565.</citation>
      <PMID>27404403</PMID>
    </reference>
    <reference>
      <citation>Fernandez-Banares F, Casanova MJ, Arguedas Y, Beltran B, Busquets D, Fernandez JM, Fernandez-Salazar L, Garcia-Planella E, Guagnozzi D, Lucendo AJ, Mancenido N, Marin-Jimenez I, Montoro M, Piqueras M, Robles V, Ruiz-Cerulla A, Gisbert JP; Spanish Microscopic Colitis Group (SMCG). Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Aliment Pharmacol Ther. 2016 Feb;43(3):400-26. doi: 10.1111/apt.13477. Epub 2015 Nov 24.</citation>
      <PMID>26597122</PMID>
    </reference>
    <reference>
      <citation>Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000 Oct;95(10):2831-7. doi: 10.1111/j.1572-0241.2000.03194.x.</citation>
      <PMID>11051356</PMID>
    </reference>
    <reference>
      <citation>Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007 Jul;19(7):567-74. doi: 10.1097/MEG.0b013e328058ed76.</citation>
      <PMID>17556903</PMID>
    </reference>
    <reference>
      <citation>Wagner M, Peterson CG, Stolt I, Sangfelt P, Agnarsdottir M, Lampinen M, Carlson M. Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study. Scand J Gastroenterol. 2011 Jul;46(7-8):849-54. doi: 10.3109/00365521.2011.571707. Epub 2011 May 11.</citation>
      <PMID>21557718</PMID>
    </reference>
    <reference>
      <citation>Stoicescu A, Becheanu G, Dumbrava M, Gheorghe C, Diculescu M. Microscopic colitis - a missed diagnosis in diarrhea-predominant irritable bowel syndrome. Maedica (Bucur). 2012 Jan;7(1):3-9.</citation>
      <PMID>23118812</PMID>
    </reference>
    <reference>
      <citation>Batista L, Ruiz L, Ferrer C, Zabana Y, Aceituno M, Arau B, Andujar X, Esteve M, Fernandez-Banares F. Usefulness of fecal calprotectin as a biomarker of microscopic colitis in a cohort of patients with chronic watery diarrhoea of functional characteristics. Dig Liver Dis. 2019 Dec;51(12):1646-1651. doi: 10.1016/j.dld.2019.07.002. Epub 2019 Aug 2.</citation>
      <PMID>31383457</PMID>
    </reference>
    <reference>
      <citation>Palsson OS, Whitehead W, Tornblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020 Apr;158(5):1262-1273.e3. doi: 10.1053/j.gastro.2019.12.021. Epub 2020 Jan 7.</citation>
      <PMID>31917991</PMID>
    </reference>
    <reference>
      <citation>Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57. doi: 10.1517/14656566.5.6.1347.</citation>
      <PMID>15163279</PMID>
    </reference>
    <reference>
      <citation>Lanas A. Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. Am J Med Sci. 2009 Aug;338(2):96-106. doi: 10.1097/MAJ.0b013e3181ad8cd3.</citation>
      <PMID>19680014</PMID>
    </reference>
    <reference>
      <citation>Sandler RS, Keku TO, Woosley JT, Sandler DP, Galanko JA, Peery AF. Obesity is associated with decreased risk of microscopic colitis in women. World J Gastroenterol. 2022 Jan 14;28(2):230-241. doi: 10.3748/wjg.v28.i2.230.</citation>
      <PMID>35110947</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 28, 2023</study_first_submitted>
    <study_first_submitted_qc>September 1, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 11, 2023</study_first_posted>
    <last_update_submitted>September 1, 2023</last_update_submitted>
    <last_update_submitted_qc>September 1, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 11, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Inflammatory bowel disease (IBD)</keyword>
    <keyword>clinical scoring</keyword>
    <keyword>chronic watery diarrhea</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Colitis</mesh_term>
      <mesh_term>Colitis, Microscopic</mesh_term>
      <mesh_term>Diarrhea</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06031064
  org study id: P/22-108
  nct id: NCT06031064
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  Chronic watery diarrhoea is a very common problem in the population and most of these
        patients will be referred for colonoscopy. If no macroscopic findings are observed during
        colonoscopy to justify the diarrhoea, serial colonic biopsies will be taken to rule out
        Microscopic Colitis (MC). However, it has been estimated that only 10-15% of these patients
        will be diagnosed with MC after colonoscopy. Therefore, about 80% of the biopsies collected
        and analysed will not be useful to establish a diagnosis, considerably increasing costs.
  
        To predict the risk of developing MC, a new promising clinical scoring system has been
        recently developed. This score will be useful in the diagnostic work-up of chronic watery
        diarrhoea to prioritize colonoscopy with stepwise colonic biopsies in patients with a
        positive highly specific score for MC. In cases with a negative score, colonoscopy plus
        biopsies should be performed only if other diagnostic tests are negative.
  
        The aim of this current study is to externally validate the new scoring system to predict MC
        in patients with chronic watery diarrhoea.
  Two diagnostic scoring systems have been proposed to predict the risk of developing MC: 1)
        The Kane score (sensitivity (SN) 96%; specificity (SP) 46%) combines eight risk factors,
        including female sex, age over 50 years, weight loss, absence of abdominal pain, and use of
        proton pump inhibitors (PPIs) and non-steroidal anti-inflammatory drugs (NSAIDs), presence of
        nocturnal diarrhoea and diarrhoea duration of less than 6 months. 2) The Cotter score (SN
        93%; SP 49%) includes age ≥55 years, duration of diarrhoea ≤6 months, ≥5 bowel movements per
        day, body mass index <30 kg/m2, current smoking, and current use of selective serotonin
        reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors and NSAIDs. However, both
        scoring systems have been derived from retrospective studies and watery chronic diarrhoea,
        the hallmark clinical symptom of MC, was not well defined.
  
        Besides MC risk factors, faecal markers could also be useful for MC screening. Most studies
        have found that 60-75% of the patients with active collagenous colitis, a subtype of MC, have
        elevated faecal calprotectin levels. Moreover, a recent study showed that faecal calprotectin
        concentrations >100 μg/g (AUC, 0.73) showed a 67% sensitivity and 75% specificity to predict
        MC.
  
        To further assess the value of the Kane and Cotter scoring systems and to derive a new score
        including faecal calprotectin aiming to increase specificity, the investigators performed a
        prospective observational two-centres study. Chronic watery diarrhoea was defined as ≥2
        watery stools (Bristol 6-7) per day, of frequent occurrence (≥3 times per week), of at least
        1 month duration. A registry of demographic and clinical characteristics (VAS of 0-100 of
        abdominal pain and abdominal distension, presence of nocturnal diarrhoea, urgency and faecal
        incontinence, smoking, body mass index, weight loss, use of drugs) was performed. The study
        included 118 patients with chronic watery diarrhoea, from which 41 were diagnosed with MC (21
        lymphocytic colitis, 16 collagenous colitis and 4 paucicellular colitis) and obtained lower
        SN and SP values than those published of the Cotter (SN 78%; SP 57%) and Kane (SN 78%; SP
        38%) scores. The AUC of both scores was 0.71 and 0.66, respectively. The multivariate
        analysis identified 5 variables associated with MC: >5 stools/day (OR 12.5), duration of
        diarrhoea ≤8 months (OR 5), regular use of low-dose acetylsalicylic acid (ASA) (OR 4), BMI
        ≤26 Kg/m2 (OR 4.1) and faecal calprotectin >500 µg/g (OR 5.5). A new score was developed
        using the variables mentioned above with an AUC of 0.86 (p<0.001 vs. Kane and Cotter scores).
        A score >10 had a sensitivity of 61.5% and a specificity of 92%. A score >17 gave a
        specificity of 100% with a sensitivity of 36%. The score was internally validated using
        bootstrapping techniques.
  
        Although promising, the new scoring system must be externally validated before generalizing
        its use in clinical practice.
  observational model: Cohort
  time perspective: Prospective
  measure: Percentage of patients diagnosed with Microscopic Colitis (MC)
  time frame: up to 2 months (after clinical and histological assessment)
  description: MC diagnosis based on clinical and histological criteria as established by the European guidelines on microscopic colitis: Miehlke S, Guagnozzi D, Zabana Y, et al. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations [published online ahead of print, 2021 Feb 22]. United European Gastroenterol J. 2021;9(1):13-37
  measure: Faecal calprotectin concentration (μg/g)
  time frame: at inclusion (prior to colonoscopy)
  description: Faecal calprotectin concentration (μg/g) will be measured using a DSX system analyser (Dynex technologies, Worthing, UK) by ELISA (BÜHLMANN fCAL, Schönenbuch, Switzerland or similar)
  arm group label: Patients with chronic watery diarrhoea and clinical suspicion of MC
  Frozen colon tissue and faecal sample
  study pop: 
  sampling method: Probability Sample
  criteria: 
  gender: All
  minimum age: 40 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Yamile Zabana, MD, PhD
  email: yzabana@gmail.com
  facility: 
  status: Recruiting
  country: Spain
  citation: Miehlke S, Guagnozzi D, Zabana Y, Tontini GE, Kanstrup Fiehn AM, Wildt S, Bohr J, Bonderup O, Bouma G, D'Amato M, Heiberg Engel PJ, Fernandez-Banares F, Macaigne G, Hjortswang H, Hultgren-Hornquist E, Koulaouzidis A, Kupcinskas J, Landolfi S, Latella G, Lucendo A, Lyutakov I, Madisch A, Magro F, Marlicz W, Mihaly E, Munck LK, Ostvik AE, Patai AV, Penchev P, Skonieczna-Zydecka K, Verhaegh B, Munch A. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. United European Gastroenterol J. 2021 Feb 22;9(1):13-37. doi: 10.1177/2050640620951905. Online ahead of print.
  PMID: 33619914
  citation: Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005 Aug 15;22(4):277-84. doi: 10.1111/j.1365-2036.2005.02561.x.
  PMID: 16097993
  citation: Larsson JK, Sjoberg K, Vigren L, Benoni C, Toth E, Olesen M. Chronic non-bloody diarrhoea: a prospective study in Malmo, Sweden, with focus on microscopic colitis. BMC Res Notes. 2014 Apr 14;7:236. doi: 10.1186/1756-0500-7-236.
  PMID: 24731750
  citation: Fernandez-Banares F, de Sousa MR, Salas A, Beltran B, Piqueras M, Iglesias E, Gisbert JP, Lobo B, Puig-Divi V, Garcia-Planella E, Ordas I, Andreu M, Calvo M, Montoro M, Esteve M, Viver JM; RECOMINA Project, GETECCU Grupo Espanol de Enfermedades de Crohn y Colitis Ulcerosa. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013 Feb;19(2):411-7. doi: 10.1002/ibd.23009.
  PMID: 23344243
  citation: Kane JS, Rotimi O, Everett SM, Samji S, Michelotti F, Ford AC. Development and validation of a scoring system to identify patients with microscopic colitis. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1125-31. doi: 10.1016/j.cgh.2014.12.035. Epub 2015 Jan 20.
  PMID: 25616029
  citation: Kane JS, Sood R, Law GR, Gracie DJ, To N, Gold MJ, Ford AC. Validation and modification of a diagnostic scoring system to predict microscopic colitis. Scand J Gastroenterol. 2016 Oct;51(10):1206-12. doi: 10.1080/00365521.2016.1186221. Epub 2016 May 31.
  PMID: 27243102
  citation: Cotter TG, Binder M, Harper EP, Smyrk TC, Pardi DS. Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. J Clin Gastroenterol. 2017 Mar;51(3):228-234. doi: 10.1097/MCG.0000000000000565.
  PMID: 27404403
  citation: Fernandez-Banares F, Casanova MJ, Arguedas Y, Beltran B, Busquets D, Fernandez JM, Fernandez-Salazar L, Garcia-Planella E, Guagnozzi D, Lucendo AJ, Mancenido N, Marin-Jimenez I, Montoro M, Piqueras M, Robles V, Ruiz-Cerulla A, Gisbert JP; Spanish Microscopic Colitis Group (SMCG). Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Aliment Pharmacol Ther. 2016 Feb;43(3):400-26. doi: 10.1111/apt.13477. Epub 2015 Nov 24.
  PMID: 26597122
  citation: Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000 Oct;95(10):2831-7. doi: 10.1111/j.1572-0241.2000.03194.x.
  PMID: 11051356
  citation: Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007 Jul;19(7):567-74. doi: 10.1097/MEG.0b013e328058ed76.
  PMID: 17556903
  citation: Wagner M, Peterson CG, Stolt I, Sangfelt P, Agnarsdottir M, Lampinen M, Carlson M. Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study. Scand J Gastroenterol. 2011 Jul;46(7-8):849-54. doi: 10.3109/00365521.2011.571707. Epub 2011 May 11.
  PMID: 21557718
  citation: Stoicescu A, Becheanu G, Dumbrava M, Gheorghe C, Diculescu M. Microscopic colitis - a missed diagnosis in diarrhea-predominant irritable bowel syndrome. Maedica (Bucur). 2012 Jan;7(1):3-9.
  PMID: 23118812
  citation: Batista L, Ruiz L, Ferrer C, Zabana Y, Aceituno M, Arau B, Andujar X, Esteve M, Fernandez-Banares F. Usefulness of fecal calprotectin as a biomarker of microscopic colitis in a cohort of patients with chronic watery diarrhoea of functional characteristics. Dig Liver Dis. 2019 Dec;51(12):1646-1651. doi: 10.1016/j.dld.2019.07.002. Epub 2019 Aug 2.
  PMID: 31383457
  citation: Palsson OS, Whitehead W, Tornblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020 Apr;158(5):1262-1273.e3. doi: 10.1053/j.gastro.2019.12.021. Epub 2020 Jan 7.
  PMID: 31917991
  citation: Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57. doi: 10.1517/14656566.5.6.1347.
  PMID: 15163279
  citation: Lanas A. Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. Am J Med Sci. 2009 Aug;338(2):96-106. doi: 10.1097/MAJ.0b013e3181ad8cd3.
  PMID: 19680014
  citation: Sandler RS, Keku TO, Woosley JT, Sandler DP, Galanko JA, Peery AF. Obesity is associated with decreased risk of microscopic colitis in women. World J Gastroenterol. 2022 Jan 14;28(2):230-241. doi: 10.3748/wjg.v28.i2.230.
  PMID: 35110947
  responsible party type: Sponsor
  mesh term: Colitis
  mesh term: Colitis, Microscopic
  mesh term: Diarrhea